| Identification | Back Directory | [Name]
GATIFLOXACIN MESYLATE | [CAS]
316819-28-0 | [Synonyms]
AM 1155 mesylate
PD 135432 mesylate)
GATIFLOXACIN MESYLATE
BMS 206584-01 mesylate
GATIFLOXACIN MESYLATE USP/EP/BP
Gatifloxacin mesylate
(AM 1155 mesylate
AM 1155 MESYLATE;BMS 206584-01 MESYLATE;PD 135432 MESYLATE
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(3-Methyl-1-piperazinyl)-4-oxo-, MonoMethanesulfonate (9CI) | [Molecular Formula]
C19H22FN3O4.CH4O3S | [MDL Number]
MFCD09954660 | [MOL File]
316819-28-0.mol | [Molecular Weight]
471.503 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [InChIKey]
PMMNVFFMFJMFDB-UHFFFAOYSA-N | [SMILES]
S(=O)(=O)(O)C.C1(=C(N2CC(C)NCC2)C(OC)=C2N(C3CC3)C=C(C(=O)C2=C1)C(=O)O)F |
| Hazard Information | Back Directory | [Uses]
Gatifloxacin mesylate is a fourth generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity. It is able to inhibit bacterial type II topoisomerase (IC50 = 13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA rotamase (IC50 = 0.109 μg/ml). It can be used to treat bacterial conjunctivitis in vivo, and its injection can treat acute urinary tract infections with efficacy comparable to levofloxacin hydrochloride injection[1]. | [in vivo]
Gatifloxacin mesylate (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with Nocardia brasiliensis[4]. | Animal Model: | Female BALB/c mice with Nocardia brasiliensis in the right hind footpad.
| | Dosage: | 100 mg/kg | | Administration: | Subcutaneous injection; 3 times a day; 30 days | | Result: | Reduced the production of lesions in mice. |
| [IC 50]
Quinolone; Topoisomerase II: 36.7 μM (IC50) | [References]
[1] L. DENG. Observation on the curative effect of gatifloxacin mesylate injection in the treatment of acute urinary tract infections[J]. 国际医药卫生导报, 2009. DOI:10.3760/CMA.J.ISSN.1007-1245.2009.05.025. |
|
|